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Cancer associated epigenetic transitions
identified by genome-wide histone methylation
binding profiles in human colorectal cancer
samples and paired normal mucosa
Stefan Enroth1,5†, Alvaro Rada-Iglesisas1,2,6†, Robin Andersson1,7, Ola Wallerman2, Alkwin Wanders2, Lars Påhlman3,
Jan Komorowski1,4 and Claes Wadelius2*
Abstract
Background: Despite their well-established functional roles, histone modifications have received less attention
than DNA methylation in the cancer field. In order to evaluate their importance in colorectal cancer (CRC), we
generated the first genome-wide histone modification profiles in paired normal colon mucosa and tumor samples.
Methods: Chromatin immunoprecipitation and microarray hybridization (ChIP-chip) was used to identify promoters
enriched for histone H3 trimethylated on lysine 4 (H3K4me3) and lysine 27 (H3K27me3) in paired normal colon
mucosa and tumor samples from two CRC patients and for the CRC cell line HT29.
Results: By comparing histone modification patterns in normal mucosa and tumors, we found that alterations
predicted to have major functional consequences were quite rare. Furthermore, when normal or tumor tissue
samples were compared to HT29, high similarities were observed for H3K4me3. However, the differences found for
H3K27me3, which is important in determining cellular identity, indicates that cell lines do not represent optimal
tissue models. Finally, using public expression data, we uncovered previously unknown changes in CRC expression
patterns. Genes positive for H3K4me3 in normal and/or tumor samples, which are typically already active in normal
mucosa, became hyperactivated in tumors, while genes with H3K27me3 in normal and/or tumor samples and
which are expressed at low levels in normal mucosa, became hypersilenced in tumors.
Conclusions: Genome wide histone modification profiles can be used to find epigenetic aberrations in genes
associated with cancer. This strategy gives further insights into the epigenetic contribution to the oncogenic
process and may identify new biomarkers.
Background
Cancer has been traditionally considered a genetic and
cytogenetic disease, but recent years have brought epige-
netics to the forefront of cancer research [1,2]. Altered
DNA methylation is nowadays considered a hallmark of
neoplasia, including two different phenomena in cancer
cells: global hypomethylation and CpG-promoter hyper-
methylation of tumor suppressor genes [1,2]. The
importance of epigenetic alterations in cancer is further
highlighted by their use in diagnosis and by the develop-
ment of new therapeutic strategies aiming at correcting
them [3].
Although histone modifications play major roles in
processes such as transcription, replication and DNA
repair, their oncogenic importance is not yet well estab-
lished. However, several lines of evidence suggest that
alterations in histone modifications are crucial in cancer
development and progression. Global changes in histone
H4 modifications seem to be universal markers of
malignant transformation [4], while other histone marks
predict the prognosis of prostate cancer [5]. Two of the
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most relevant histone modifications, both in general and
from a cancer perspective, are histone H3 lysine 4 tri-
methylation (H3K4me3), which is found in promoters of
active genes and histone H3 lysine 27 trimethylation
(H3K27me3), which is preferentially associated with pro-
moters of inactive genes [6]. SMYD3, a histone methyl
transferase specific for H3K4, is over expressed in color-
ectal, hepatic and breast cancers, suggesting that H3K4
hypermethylation can occur at promoters of oncogenes
[7]. MLL, another H3K4 methyltransferase, is frequently
translocated in various forms of leukaemia [8] and the
polycomb protein EZH2, a H3K27 specific histone
methyl-transferase, is altered in multiple types of cancer
[9]. Furthermore, recent reports suggest that H3K27me3
mediated silencing of tumor suppressor genes is a fre-
quent event in prostate cancer [10,11].
Human genome-wide binding profiles for H3K4me3,
H3K27me3 and other histone modifications have been
previously generated, but in most cases, cancer cell lines
were used as biological material [10,12]. Although this
offers important insights into the functionality of the
histone marks, it might not be optimal when investigat-
ing their importance in oncogenesis, as exemplified by
the discrepancy between H3K27me3 profiles in normal
tissue and cell lines of the same origin [13], or by
increased DNA methylation in embryonic stem cells
(ESCs) due to in vitro culture [14]. Therefore, in order
to establish how chromatin is altered during the onco-
genic process, histone modification profiles from normal
and tumor tissue samples are most desirable. However,
and to the best of our knowledge, this has only been
reported in liver [15] and pheochromocytoma [16].
Colon adenocarcinomas display numerous epigenetic
alterations, including hypermethylation of tumor suppres-
sor genes and loss of imprinting at IGF2/H19 [17]. Inter-
estingly, the major risk factor for CRC is age and
epigenetic lesions accumulate with aging and contribute to
cell transformation [18]. Despite the evident role of histone
modifications in colon cancer, histone modification profiles
have not been analyzed in coupled normal and tumor
colon samples. Here we present the first genome-wide
maps of H3K4me3 and H3K27me3 in paired normal and
tumor samples from CRC patients. We identify previously
unknown changes in the methylation statuses between the
normal and tumor samples and correlate these to CRC-
related pathway and function. Taken together, these data
could be an important resource in understanding the epi-
genetic alterations associated to CRC.
Results
H3K4me3 and H3K27me3 binding profiles in paired
normal and tumor samples from CRC patients
We generated enrichment profiles for H3K4me3 and
H3K27me3 in tumor samples from two CRC patients,
for which the profiles in normal mucosa have previously
been generated [13] and for the colon adenocarcinoma
cell line HT29. After determining the enriched regions
(Figure 1A) for each modification in normal and tumor
samples (Table 1 and Additional file 1), they were anno-
tated to human genes using the UCSC knownGenes
databases [19] (Table 1) (Methods).
Signal footprints were created around transcription
start sites and both the H3K4me3 and H3K27me3 pat-
terns were similar to those reported [20-22] in other cell
types (Figure 1B). As a quality control, microarray
expression data from public repositories for normal
colon, CRC tumors and HT29 were used [23]. Although
the expression data comes from unrelated patient mate-
rial, the objective was to study genome wide trends in
transcription given the epigenetic status and not single
gene effects where expression from the same patient
material is essential. The expression of H3K4me3
enriched genes were higher than average, while
H3K27me3 genes tended to be silent (Figure 2A). Biva-
lent and especially semi-bivalent (Methods) gene groups
included fewer genes and were poorly expressed,
although with higher variation in expression. The quality
of our data is also supported by previous validation of
H3K4me3 and H3K27me3 enriched regions by qPCR in
normal colon [13] demonstrating that ChIP-chip analy-
sis can be performed using human tissue as biological
material.
For regions with associated transcripts, gene ontology
(GO) annotations were obtained and an analysis was
performed for over/under representation of terms com-
pared to a whole genome background (Figure 2B, Meth-
ods). The H3K4me3 and H3K27me3 gene groups have
opposite functions and bivalent and semi-bivalent gene
groups lie closer in functional space to H3K27me3 than
H3K4me3 genes, as also suggested by expression data.
Therefore, bivalent and semi-bivalent genes were treated
as part of H3K27me3 gene groups for most subsequent
analysis. In general, H3K4me3 fractions displayed over-
representation in metabolic processes while H3K27me3
fractions showed enrichment in developmental cate-
gories. The overrepresented categories in H3K4me3 and
H3K27me3 genes were very similar in the HT29 cell
line.
H3K4me3 and H3K27me3 profiles are similar between
normal and tumor samples but distinct compared to CRC
cell lines
Using all probes we calculated the Pearson’s correlation
between all combinations of histone modifications,
patient material (normal/tumor) and cell line (Addi-
tional file 2, Table S1). In all cases the correlation
between any patient materials was always strongest
when that material was compared to another patient
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material. In some cases, e.g. patient 1 tumor
H3K27me3/K4me3, the correlation was highest with
patient 2 normal H3K27me3/K4me3 rather than the
HT29 cancer cell line. This pattern is more evident
when regarding enriched regions only and by counting
overlapping enriched regions, a relatively high similarity
between normal and tumor samples and between
patients for both H3K4me3 (Figure 3) and H3K27me3
was noted (Table 1 and Additional file 2, Figure S6).
Around 60% of the H3K4me3 and 35% of H3K27me3
regions in both patients are common between normal
and tumor tissue. When annotated transcripts rather
than individual regions were used these numbers rise to
around 70% and 50% respectively. Considering
H3K4me3 genes, HT29 targets showed large overlaps
with both patients normal and tumor samples (Table 1-
2). The overlaps for the adenocarcinoma cell line
SW480 [24] were quite poor (10-20%) both with tissue
samples and HT29 (Table 2). We also noted that the
number (around 1%, 80-431) of bivalent regions
detected in promoters here is lower than the number
detected in a previous study [25] on differentiated cells
Figure 1 ChIP-chip signals. (A) Signal example from the TWIST1-gene (chr7) with data from patient 2. Left panel shows individual probes in
replicates for all signals after analysis in TAS. Right panel shows normalized and averaged signal in terms of standard deviations (y-axis).
Detected regions and location (HG18) of the TWIST1 gene is also marked out. (B) Footprints of normal and tumor K4/K27 signal in patient 1
around the TSS’s (left) of genes associated with enriched regions in each group separately and centred around genes associated with bivalent
regions (right) in normal and tumor respectively.
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Table 1 Number of annotated geneSymbols and enriched regions.
Regions geneSymbols
Patient 1 Normal Patient 1 Tumour Patient 2 Normal Patient 2 Tumour HT29
K4 K27 K4 K27 K4 K27 K4 K27 K4 K27
Patient1 Normal K4 6136 6065 431 4570 552 3898 450 3552 302 4323 387
K27 3137 0 1775 191 926 190 1267 146 744 148 359
Patient1 Tumour K4 6783 0 0 7416 344 4946 173 4430 119 5771 262
K27 3177 0 0 0 1981 315 1078 244 756 315 457
Patient2 Normal K4 5316 0 0 0 0 5756 174 3934 125 4535 248
K27 3594 0 0 0 0 0 1976 119 877 143 422
Patient2 Tumour K4 5670 0 0 0 0 0 0 5406 80 4106 251
K27 3524 0 0 0 0 0 0 0 1623 112 430
HT29 K4 6544 0 0 0 0 0 0 0 0 6938 223
K27 2612 0 0 0 0 0 0 0 0 0 1494
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Figure 2 Expression patterns and functional classification. (A) Expression profiles in associated genes from normal patient material (left),
tumor patient material (middle) and HT29 (right). In each group, the average expression on the entire array, the expression in K4, K27, bivalent
and semi-bivalent genes respectively are depicted. (B) Hierarchical clustering of p-values of GO (Biological Process) terms. Over/under-
representation is denoted by red/blue color and level of significance by color intensity. The three major clusters are made up by K4 fractions,
K27 fractions and Bivalent/Semi-bivalent.
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(CDC36+) where around 3% (693) of the genes were
found to have bivalently marked promoters. Cui et al
[25] performed their study using next generation
sequencing and called more regions enriched through-
out the genome suggesting that the main cause of differ-
ence lies in stringency of the downstream analysis.
Detection of genes and pathways with chromatin state
differences between tumor and normal samples
To identify the genomic regions differing in their chro-
matin state between normal and tumor tissues (Meth-
ods), the results were split in fifteen so called transitions
each representing a combined state of one or more
marks in normal and tumor. Three major groups were
created; i) gaining or loosing a single mark, ii) keeping a
mark and iii) changes involving both marks (Figure 4A
and Additional file 2, Figure S4A). The majority fall into
category ii), that is no change, and category i) which is
in agreement with the large overlaps reported in the
previous section (Additional file 2,Table S2).
Category iii) implies chromatin transitions between
normal and tumor that can result in a switch from tran-
scriptionally active (e.g. H3K4me3) to inactive states (e.
g. H3K27me3) or vice verse. Therefore, it is the most
interesting category in terms of potentially functional
consequences from an oncogenic point of view. How-
ever, only 4 genes were common to both patients in
category iii) (Additional file 2, Table S2). KLF7 (N K27
to T K4), a transcription factor belonging to the KLF
family that plays critical roles in differentiation, develop-
ment, and maintenance of tissue homeostasis [26], but,
to the best of our knowledge, without a specific role in
colon cancer. The remaining three common genes
(EBF3, DKFZp667I0324 and RBMS1) were all bivalent in
normal tissue but lost all their histone methylation in
tumor. Among these genes, 2 have previously been
functionally characterized. EBF3 is a transcription factor
reported to be a tumor suppressor gene [27] with
observed silencing in CRC cell line HCT116, was biva-
lent in normal and lost both marks in tumor. RBMS1 is
Figure 3 Overlaps between genes marked with H3K4me3 in different samples. (A) Overlaps between genes associated with K4 enriched
regions detected in patient 1 normal and tumor tissue. (B) Overlaps between genes associated with K4 enriched regions detected in tumor
tissue from patient 1, tumor patient 2 and HT29. (C) Same as (B) but for normal tissue from patient 1 and 2.
Table 2 Comparisons between H3K27me3 target genes in colon tissue samples and CRC cell lines.
Patient 1 Patient 2 Cell Lines
Normal Tumor Normal Tumor HT29 SW480
K27 K27 K27 K27 K27 SUZ12
Patient 1 Normal K27 600 310 399 237 138 74
Tumor K27 660 349 242 164 88
Patient 2 Normal K27 636 282 154 84
Tumor K27 512 151 82
Cell Lines HT29 K27 512 67
SW480 SUZ12 447
The different gene categories considered (in bold) consisted of the genes marked by H3K27me3 in normal or tumor samples from patient 1 or patient 2, genes
bound by H3K27me3 in HT29 CRC cell line and genes bound by SUZ12 in SW480 CRC cell line. Only genes were both H3K27me3 data in tissues samples and
HT29 cell line and SUZ12 data in SW480 cell line were available were considered (total = 7393), which was limited by the coverage of the arrays used. The
numbers in the diagonal of the table (in bold) indicate all genes included in each category, while the remaining numbers indicate the overlaps between each
pair of categories considered in each case.
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a transcription factor that has been suggested as an
important factor in inducing apoptosis in mice [28], and
has been shown to have predictive power on colorectal
cancer recurrence in human patient cohorts [29]. A
number of transitions were specific to individual
patients e.g. from category iii). Some genes had
H3K4me3 in normal colon which changed to
H3K27me3 in tumors, e.g. in patient 1 HOXB13 and
KREMEN2, which are frequently down regulated in
CRC [30,31]. Among genes with a silent state
(H3K27me3 mark) in normal colon that became active
in CRC samples (gained H3K4me3) there were several
well-characterized oncogenes [32-36], e.g. in patient 1
FLI1, WWTR1 &ZEB2 and in patient 2 TACSTD2
&TWIST1 (Figure 1A and Additional file 2, Figure S5
(patient 1)), the last two with proposed importance in
CRC [32,35].
Several genes in categories i) and ii) were found to
have the same transitions in both patients. Both our
patients have H3K4me3 on the PTGER2 gene in normal
tissue and gained H3K27me3 in the tumor, which offers
a mechanistic explanation to the previously reported
expression pattern [37] of this gene in colorectal cancer.
In addition, three genes common to both patients which
carried bivalent marks in normal and lost H3K4me3 in
tumor, LHX9, PKNOX2 and LBXCOR1 and one,
PRDM8, lost the H3K27me3 in tumor, all of which are
transcription factors with unknown function in colon.
The chromatin states of genes involved in biological
pathways with relevance in CRC biology [38] was speci-
fically investigated. The WNT-signalling pathway has
been implicated in CRC [39,40], with the APC gene fre-
quently silenced or mutated. Patient 1 has tumor repres-
sive transitions in the APC gene and tumor activating
Figure 4 Normal-to-tumor histone modification transitions. (A) Normal-to-tumor transition graphs detected in patient 1 separated by
starting condition. The number of associated genes is given below each of the 15 monitored transitions. The 15 transitions are grouped into 3
categories given by the color of the target. Below each start condition a region-centered footprint is drawn depicting the change in signal over
the detected genomic regions. The selected transitions are highlighted in bold in the graph. (B) Part of the WNT-pathway color coded by
change in epigenetic markers in patient 1. Red indicate an activating change (’N -’ to ‘T K4’, ‘N K27’ to ‘T K4’ or ‘N Biv’ to ‘T K4’) while Blue
indicate an repressive change (’N -’ to ‘T K27’, ‘N K4’ to ‘T K27’, ‘N K4’ to ‘T -’, ‘N K4’ to ‘T Biv’ or ‘N Biv’ to ‘T K27’).
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transitions in Axin, PP2A, b-catenin and in many down-
stream factors along the WNT-signalling pathway affect-
ing transcription, cell cycle and CRC development,
especially within the TCF/LEF family [41,42] (Figure
4B). This suggests a repression on the b-catenin degra-
dation complex and an up regulation of b-catenin
dependent gene expression with downstream effects on
the cell cycle [43]. Recently, a dual role of APC in the
WNT-signalling pathway has been suggested with both
activating and repressing mechanisms [44] which could
explain the patterns found in patient 2 where APC has
gained activating markers (Additional file 2, Figure S4B)
In addition, patient 1 shows an activation of several
known repressors of the WNT-pathway. CtBP represses
E-cadherin which in turn is a tumor repressor restrict-
ing tumor cell motility and invasion [45]. The ubiquitin
ligase Cul1 is part of a mechanism targeting proteins for
degradation and thus an important factor in cell cycle
control. Specifically, Cul1 acts as an oncogene that
forms complexes that specifically target the cell cycle
inhibitor p27/Kip1 for degradation [46].
Global expression changes of H3K4me3 and H3K27me3
targets in CRC
Although epigenetic transitions within category iii) are
expected to have important functional consequences,
few examples are detected in a given CRC patient.
Therefore, these examples are less likely to have large-
scale changes in gene expression. More global relation-
ships between chromatin state and gene expression were
analyzed using all epigenetic transitions involving more
than 100 genes i.e. maintenance of H3K4me3 or
H3K27me3, tumor loss of H3K4me3 or H3K27me3 as
well as tumor gain of H3K4me3 or H3K27me3. Micro-
array expression data for paired normal and tumor sam-
ples from 24 CRC patients [23] were used, and the
expression changes between normal and cancer samples
for the genes included in each transition category
(patient specific) was compared (Figure 5 and Additional
file 2, Figures S1-S3).
Genes in transitions where H3K4me3 was maintained
or specifically gained in tumors, showed significantly
higher expression levels in cancer samples (Figure 5A
and Additional file 2, Figure S2). Opposite expression
shifts were observed for genes that kept, gained or lost
H3K27me3 in the tumor samples (Figure 5B, Additional
file 2, Figure S2). The H3K4me3 and H3K27me3 gene
groups also differed in the baseline expression in normal
samples as H3K4me3 genes were highly expressed, while
most H3K27me3 genes showed low expression levels.
Furthermore, genes in H3K4me3 transition groups are
typically already activated in normal tissue and become
“hyperactivated” in tumors, while genes in H3K27me3
transition groups are lowly expressed in normal colon
and become “hypersilenced” in cancer samples. The
generality of the observations is supported by (i) the
similar expression shifts obtained when considering the
epigenetic transition groups from either patient 1 and
patient 2 (Additional file 2, Figure S2A); and (ii) from a
second expression data set with paired normal and
tumor samples from 9 CRC obtained in a different array
platform [47] (Additional file 2, Figure S2 B-C).
The significantly up- or down- regulated genes in can-
cer samples in the two expression microarray data sets
described above assuming a paired sample design was
analyzed further. For both patients and microarray data
sets (Figure 5C and Additional file 2, Figure S3) genes
keeping or gaining H3K4me3 in tumors were signifi-
cantly over-represented among up-regulated genes and
significantly under-represented among down-regulated
genes. Opposite patterns were observed for genes that
kept, gained or lost H3K27me3 in tumor samples (Fig-
ure 5C and, Additional file 2, Figure S3). These results
indicate that at least for a fraction of genes the reported
expression changes may be of large magnitude and
occur in most patients. We gathered microarray expres-
sion data for HT29 [23] and considered the same epige-
netic transitions as described above, and can report that
the tendencies towards hyperactivation or hypersilencing
of H3K4me3 and H3K27me3 gene groups became even
more pronounced in HT29 cells (Figure 5D-E and Addi-
tional file 2, Figure S4).
Hypersilencing of some H3K27me3 genes may involve
loss of H3K27me3 and DNA hypermethylation
The expression levels between normal colon, tumor
samples and HT29 cell line for all H3K4me3 and
H3K27me3 enriched genes were compared in the three
samples types and for those genes that were shared or
unique to any of them. The overall H3K4me3 or
H3K27me3 gene groups showed progressive hyperacti-
vation and hypersilencing in tumor and HT29 cells
compared to normal colon, respectively (Figure 6A,B).
This was also true for the genes with shared histone
modification states, but less obvious in some of the
unique groups. For the H3K27me3 unique groups, the
hypersilencing pattern was still found for those genes
carrying that histone mark only in normal colon sam-
ples (Figure 6B).
It has been recently reported [12] that genes enriched
in H3K27me3 in normal prostate frequently become
DNA hypermethylated and lose H3K27me3 in prostate
cancer cell lines. Furthermore, DNA hypermethylation
seems to be exacerbated by in vitro culture [14]. In
order to test whether genes with the H3K27me3 mark
in normal colon overlapped more with genes hyper-
methylated in CRC than genes that carried the histone
mark in tumor samples, the lists of H3K27me3 genes
Enroth et al. BMC Cancer 2011, 11:450
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Figure 5 Expression patterns in relation to histone modification transitions. (A,B) Expression for paired normal colon (red) and tumor (blue)
samples from 24 CRC patients was gathered from GEO public repository (GSE10950). Only genes where both expression and ChIP-chip data
were available were considered. Boxplots indicate the absolute expression levels of all genes and those transition groups involving H3K4me3 (A)
or H3K27me3 (B) for patient 1. Only transition groups with at least 100 genes were considered. The name of the transition groups and the
number of genes in each group are indicated below the boxplots. For each group of genes, the expression of all genes in all 24 normal colon
samples (red) was compared to the expression in all 24 tumor samples, with the p-value indicating the statistical significance of the expression
being higher (A) or lower (B) in tumors than in normal samples, using a paired T-test. (C) Using the same expression dataset as in (A,B), genes
that were significantly up regulated (red) or down regulated (blue) in tumors compared to normal samples were determined using a p-value <
0.001 (limma package, paired-sample design, multiple hypothesis corrected). Then, for each patient 1 transition group indicated in the X-axes, we
calculated the percentage of genes in that group represented with respect to: total of genes (grey), up-regulated genes (red) and down-
regulated genes (blue). Using a hypergeometric test we calculated if genes in the different transition groups were significantly over-represented
(*) or under-represented (**) in the up/down-regulated genes compared to the distribution in all genes, using a p-value < 0.05 as cut-off. (D,E)
For the same patient 1 gene groups as in (A,B), boxplots indicate the absolute expression levels in normal colon (red), tumor samples (blue) and
HT29 cell line (green). Normal and tumor samples data is the same as in (A,B), while HT29 expression was obtained from GSM277543 dataset.
The HT29 microarrays were analysed in parallel with the CRC samples, and all microarrays were normalized between each other.
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was compared with those previously reported as fre-
quently hypermethylated in CRC [48]. As shown in Fig-
ure 6C, both H3K27me3 genes in normal and tumor
colon samples were significantly over-represented
among DNA hypermethylated genes. This was not the
case for the HT29 genes. Over-representation was only
significant for normal colon, when considering
H3K27me3 unique groups, and in fact even a trend
towards under-representation was observed for
H3K27me3 genes unique to HT29 (Figure 6C).
Discussion
By comparing normal and tumor colon samples, it was
observed that some regions, either shared or unique to
Figure 6 Hypersilencing of some of the H3K27me3 target genes may involve loss of the histone mark and DNA hypermethylation. In
(A,B) the different gene groups presented in the bottom part of the figure correspond to all genes marked by H3K4me3 (A) or H3K27me3 (B) in
both patients normal (p1p2n) or tumor samples (p1p2t) and in HT29 cell line. The Shared category included all those genes shared between
normal, tumor and HT29 gene groups, either for H3K4me3 (A) or H3K27me3 (B). Similarly, the unique groups include those genes that are only
found in normal (n_unique), tumor (t_unique) or HT29 (HT29_unique), when comparing the normal, tumor and HT29 gene groups. For each of
these groups of genes, the expression values for normal colon (red), tumor samples (blue) and HT29 cell line (green) are indicated by boxplots
and were obtained as described in Figure 4 D-E. In (C), only genes where both DNA methylation and ChIP-chip data were available were
considered (Total genes = 7547), which was mainly limited by the coverage of the arrays used in the DNA methylation study. Then, for the same
gene groups as in Figure 5B, we calculated the percentage of genes in each group represented with respect to the total of genes (grey) or
those genes hypermethylated in CRC (red) as determined in Keshet el al [48]. Using a hypergeometric test we calculated if genes in the different
gene groups were significantly over-represented (*, p.value < 0.01) among DNA hypermethylated genes compared to all genes.
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one patient, showed transitions in the chromatin states
that would suggest major functional consequences (i.e.
from normal H3K4me3 to tumor H3K27me3 or vice
verse). This resembles the results obtained after genetic
mutation analysis of all coding sequences in CRC
patients, where very few mutations are frequently shared
between patients [49]. These observations suggest that
in a given CRC patient, there could be a few major
alterations (genetic and/or epigenetic) that can be cru-
cial for tumorogenesis e.g. key components that could
disturb the WNT-pathway such as silencing of the APC
gene and activation of the b-catenin gene or up-regula-
tion of repressors of tumor suppressing genes found in
patient 1.
These few major and likely causative alterations could,
however, have major impacts on global gene expression
programs and chromatin states. Our observations sug-
gest that H3K4me3 genes, typically active in normal
colon, become “hyperactivated” in CRC. Since many of
these genes are involved in basic cellular processes, their
increased expression could merely be the result of
higher metabolic demands and proliferation rates in
tumor cells [50]. Mechanistically, a good candidate to
mediate this “hyperactivation” response is SMYD3, a
H3K4 methyltransferase frequently over-expressed in
CRC and with oncogenic function [7]. On the other
hand, H3K27me3 genes are already silent or lowly
expressed in normal colon mucosa, and seemed to
become “hypersilenced” in CRC. Down-regulation of
H3K27me3 genes could be explained by polycomb-pre-
marking of cancer-specific DNA hypermethylation
[13,51] and subsequent loss of H3K27me3 and reduced
epigenetic plasticity [12]. Due to tumor heterogeneity
between different CRC patients, it is not expected that
all normal colon H3K27me3 genes will loose the mark
and become hypermethylated in a given tumor, which
could explain why even genes that kept H3K27me3 state
in our two patients seem to be hypersilenced when con-
sidering larger patient cohorts. Finally, silencing of
genes showing specific gain of H3K27me3 in tumors has
been also reported in prostate cancer [10,11]. Mechanis-
tically, the silencing of all these H3K27me3 gene groups
may involve EZH2, which is frequently over-expressed
in CRC and other cancer types [9] and is able to interact
with and recruit DNA methyltransferases [52].
Another important aspect of the work is the evalua-
tion of how well cell lines may represent the chromatin
states of normal or tumor tissues. According to our
data, for H3K27me3, which is important in determining
cellular identity [53], cell lines could give a misleading
picture of chromatin states in tissues they are supposed
to represent. Such discrepancy seemed to increase
depending on the differentiation grade of the cell line,
suggesting that low-grade cell lines could offer better
cellular models than high grade poorly differentiated cell
lines when studying chromatin states. Furthermore, our
results and previous observations suggest that such
alterations in H3K27me3 states can arise due to a com-
bination of polycomb-premarking of DNA hypermethy-
lation, subsequent lost of H3K27me3 and exacerbated
DNA hypermethylation due to in vitro culture
[12-14,51].
One such example is the polycomb binding profiles
that were previously generated for the CRC cell line
SW480 and used as a model of differentiated cells. As
compared to ESCs, SW480 polycomb (H3K27me3) tar-
gets were not enriched in developmental related pro-
cesses [24]. Here, and previously [13], we have shown
that H3K27me3 marked genes, both in normal and
tumor colon tissues, are largely enriched in developmen-
tal processes, and in fact, they significantly overlapped
with ESC H3K27me3 targets. Therefore, we wanted to
investigate how well CRC cell lines represent the chro-
matin states of colon tissue samples (Table 2). This
might be expected since many H3K4me3 genes corre-
spond to housekeeping genes typically active in any
given cell type. On the other hand, when considering
H3K27me3 gene groups, the overlaps between normal
and tumor samples were quite high (40-60%), while
somewhat lower for HT29 (20-30%), but as described
above, H3K27me3 target genes in this cell line were still
largely related to developmental processes. Moreover,
the fact that the HT29 H3K27me3 profile, as compared
to SW480, shows higher overlap with tissues and is
enriched in developmental processes, can be explained
by the fact that HT29 is a low grade CRC cell line
(grade II), while SW480 is a high grade (grade III-IV),
poorly differentiated and highly abnormal CRC cell line.
Conclusion
In this work we generated the first coupled normal-
tumor histone modification profiles in CRC, one of the
cancer types with highest incidence in developed coun-
tries, that should provide a valuable resource for future
chromatin studies with CRC and/or gastrointestinal
focus. By studying histone modification profiles we show
that it is possible to get new insights into the epigenetic
process and discover new biomarkers for cancer. Two
such candidates discovered here are the PTGER2 and
KLF7 genes. The former gained H3K37me3 in tumor in
both our patients and the latter changed its modification
status from H3K4me3 to H3K27me3 in both patients
thus changing from activated to repressed state.
PTGER2 has previously been implicated in CRC but
further research will be needed to clarify the role of
KLF7.
Enroth et al. BMC Cancer 2011, 11:450
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Methods
Patient material
Normal colon mucosa [13] and tumor samples were
obtained from two patients diagnosed with CRC at
Uppsala University Hospital (Sweden). Immediately
upon surgery, the removed material was kept on ice.
Samples from the normal colon mucosa were taken at
least 15 cm from the localized tumor, while the tumor
sample was collected without containing parts of the
normal mucosa. A gastrointestinal pathologist per-
formed sample collection and tumor evaluation. The
patients did not receive any anticancer treatment before
surgery. All patients treated for CRC in Uppsala are
registered in the Swedish Colorectal Cancer Registry.
When admitted to the hospital they are asked to partici-
pate in that registry and also informed that biopsies will
be saved in a biobank. After having read the information
the informed consent is verbally obtained. Linked to this
we have an ethical approval to perform studies like this,
#2006/077.
ChIP and ChIP-chip
ChIP on patient samples and HT29 cells were per-
formed as previously described [13,54]. DNA amplifica-
tion, fragmentation, labelling and hybridizations of ChIP
and input DNAs were performed according to Affyme-
trix recommendations and basically as previously
described [13], using Affymetrix GeneChip Human Pro-
moter 1.0 arrays, which cover approximately from 7.5
kb upstream to 2.45 kb downstream of transcription
start sites for over 25,500 human promoters. Raw array
data has been deposited in ArrayExpress under acces-
sion number E-TABM-533
Data analysis pipeline
Affymetrix Tiling Analysis SDK revision 4 was used to
quantile normalize each pair of replicate ChIP measure-
ments together with the two input measurements and
adjusted to have a median intensity of 200 [55,56].
Replicates were combined using a sliding window of 301
bp (bandwidth = 150) assigning the median value of the
replicates in the window to the center probe. From this
point, all analysis was carried out using custom scripts
in R [57]. Log2-ratios of merged ChIP measurements
over merged input measurements were used for further
analysis. Enriched regions were defined using a Z-score
based sliding window approach. For each probe on the
array, a Z-score was calculated from the average of
log2-ratios of probes within a window of 150 base pairs
centred on the probe against the distribution of log2-
ratios on the array.
Enriched regions were defined from enriched probes
(Z-score >= 6) using the following criteria; (i) at least 2
enriched probes within the region, (ii) each enriched
probe must be flanked on both sides by existing mea-
surements within 110 base pairs (iii) the maximum gap
between enriched probes within a region is 110 base
pairs. Regions were prolonged with probes positioned
within 75 base pairs of the probes defining the tails of
the regions. Finally, regions were merged if the shortest
distance was less than 1000 base pairs.
Bivalent regions were defined as regions sharing at
least three probes between H3K4me3 and H3K27me3
regions out of which at least two were enriched. Regions
classified as having changed their methylation status
(’transitions’) between normal and tumor where required
to have at least three probes in common out of which
two needed to be commonly labelled as enriched in the
different states. In addition to this we required a Z-
score of at least 3 between the normal and tumor in the
non-changed methylation status ensuring that we are
not selecting regions immediately on opposite sides of
the chosen cut-off, i.e. clearly separating changes invol-
ving bivalent marks to single marks from instances
where a single mark is changed to another single mark.
Gene Annotation
We associated enriched regions to UCSC knownGene
transcripts if; (i) the regions were intragenic and posi-
tioned within 2.5 kb downstream of TSS or (ii) inter-
genic and positioned within 2.5 kb upstream of TSS but
not associated to any other transcript through intragenic
positioning. This window size (+/- 2.5 kb) was chosen
based on the distribution of both H3K4me3 and
H3K27me3 signals around transcription start sites. We
defined transcripts to be marked by H3K4me3 if asso-
ciated with at least one H3K4me3 region and no
H3K27me3 region. The same was done for H3K27me3
associated transcripts. Transcripts associated with both
H3K4me3 regions and H3K27me3 regions but not with
bivalent regions were called semi-bivalent.
Gene Ontology (GO) analysis
GO terms were tested using a one-sided Fishers exact
test. P-values were corrected for multiple hypotheses
testing using Bonferroni correction. The hierarchical
clustering was done using Euclidean distances and the
Ward agglomeration method. All analysis was done
using R [57]
Microarray Gene expression data sets
Microarray genes expression data sets were downloaded
from Gene Expression Omnibus (GEO) public reposi-
tories. Expression data was obtained and analyzed using
GEOquery and the ‘limma’ Bioconductor package in R
[57]. Expression data from paired tumor and normal
Enroth et al. BMC Cancer 2011, 11:450
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colon mucosa samples from 24 and 9 different CRC
patients corresponded to GSE10950 and GSE5364 data-
sets, respectively. HT29 expression data (GSM277543)
was originally generated in parallel with the tissue sam-
ples from GSE10950 dataset.
Additional material
Additional file 1: Marked genes: Lists of genes enriched with
H3K4me3 or H3K27me3 in patient material or cell line.
Additional file 2: Supplementary Material: 6 figures and 2 tables.
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CRC: colorectal cancer; H3K4me3: histone H3 lysine 4 trimethylation;
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